(Total Views: 310)
Posted On: 02/25/2021 11:59:24 AM
Post# of 145880
Quote:
with us and HGEN as front runners
Otilimab is a GM-CSF inhibitor like lenzilumab and both have mortality as part of their primary endpoints. Unless lenzilumab is somehow superior it will fail also.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)